Methylenedioxypyrovalerone (MDPV) is a synthetic stimulant of the cathinone and pyrrolidine chemical classes that became the most pharmacologically potent and clinically significant member of the "bath salts" NPS wave of the late 2000s and early 2010s. It is structurally related to pyrovalerone — an obscure appetite suppressant developed in the 1960s — through the addition of a methylenedioxy ring, and to MDPPP (the homolog without the methylenedioxy group) and other pyrrolidine cathinones.
MDPV acts as an extremely potent norepinephrine-dopamine reuptake inhibitor, without meaningful serotonergic activity. Unlike MDMA-class cathinones, MDPV has no entactogenic component — it produces purely catecholaminergic stimulation of exceptional intensity. MDPV is substantially more potent than cocaine by weight as a DAT/NET inhibitor, and its affinity for the dopamine transporter translates directly to an intense, compulsive, cocaine-like experience with dramatically shorter duration (15–30 minutes of peak effects) that drives rapid, uncontrolled redosing.
The "bath salts" era was defined primarily by MDPV. The media and public health response to incidents involving MDPV-intoxicated individuals — the face-eating incident in Miami (later found not to involve MDPV), violent psychotic episodes, and extreme self-harm — generated intense public and legislative attention. While some individual incidents were misattributed to MDPV, the genuine pharmacological basis for the psychiatric sequelae is well-documented in clinical case series and pharmacological research: MDPV produces stimulant psychosis, extreme agitation, and compulsive use patterns that exceed those of virtually any other known research chemical stimulant.
MDPV is considered by many harm reduction professionals to be one of the most dangerous substances in the research chemical market. Its exceptional potency, extremely short peak duration that drives the redosing cycle, and documented association with severe psychiatric events place it at the apex of the cathinone risk spectrum alongside high-dose A-PVP. Its use should be approached — if at all — with extraordinary caution and comprehensive harm reduction measures.
Safety at a Glance
High Risk- An Honest Risk Assessment First
- Test Your Substance
- Toxicity: Extreme Addiction Liability MDPV has among the highest documented addiction liability of any synthetic cathinone or n...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: overdose. It is strongly recommended that one use harm reduction practices when using this drug. ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 2 hrs – 7 hrsHow It Feels
The onset of vaporized MDPV is near-instantaneous and savagely intense. Within seconds, a colossal surge of stimulation tears through the nervous system. The heart slams into a rapid, pounding rhythm, every muscle tenses, and a massive wave of euphoria floods the brain with a potency that dwarfs most conventional stimulants. There is an immediate sense of limitless power and electric clarity, a feeling that every synapse is firing at maximum capacity. The rush is overwhelming, obliterating, and dangerously seductive.
At the peak, lasting perhaps twenty to forty minutes, MDPV produces a state of extreme, driven overstimulation. The mind races at a velocity that makes coherent thought difficult. Ideas fragment and multiply, each one feeling urgent and brilliant before dissolving into the next. Physical energy is explosive but directionless, manifesting as compulsive pacing, fidgeting, or repetitive behaviors. Sexual arousal can become obsessive and all-consuming. The body is under enormous stress: heart rate is dangerously elevated, blood pressure spikes, body temperature soars, and the jaw clenches with painful force. Despite these alarm signals, the subjective experience is one of godlike invincibility.
The crash arrives with punishing abruptness. The euphoria collapses within thirty to sixty minutes, replaced by a hollow, anxious emptiness and an overwhelming compulsion to redose. This compulsion is among the most powerful in all of psychopharmacology. Users describe it as a physical need, not a desire but a demand that overrides every rational consideration. The redose cycle of MDPV is relentless: each subsequent dose produces less euphoria and more toxicity. Paranoia builds with each cycle, progressing from mild suspicion to full delusional conviction. Hallucinations, both auditory and visual, emerge after prolonged use. Sleep becomes impossible. The user may enter a state of stimulant psychosis characterized by extreme paranoia, aggression, and a complete disconnection from reality.
When the binge finally ends, the aftermath is catastrophic. Physical exhaustion is total. Depression is severe and can persist for days to weeks. Cardiovascular strain may produce lingering chest pain or arrhythmia. The paranoid ideation can take days to fully resolve. The psychological damage of a prolonged MDPV session, the memory of absolute loss of control combined with the vivid recollection of the rush, creates a powerful engine of craving that defines the compound's extraordinary addiction potential.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(3)
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(1)
- Tactile hallucination— Tactile hallucinations are convincing physical sensations experienced without any corresponding exte...
Cognitive & Perceptual Effects
Visual(1)
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Cognitive(9)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
Pharmacology
Mechanism of Action
MDPV is a potent and highly selective norepinephrine-dopamine reuptake inhibitor (NDRI). It binds with high affinity to the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of dopamine and norepinephrine from the synapse. MDPV does not act as a transporter substrate — it does not cause active neurotransmitter release in the manner of amphetamine.
Exceptional DAT Potency
MDPV's DAT binding affinity is among the highest documented for any NPS stimulant. Comparative pharmacological studies have confirmed that MDPV is significantly more potent than cocaine as a DAT inhibitor, on a molar basis. This exceptional potency explains the clinical observation that MDPV produces intense dopaminergic effects at doses measured in single milligrams, and the correspondingly narrow margin between effective and toxic doses.
Absence of Serotonergic Activity
Despite the methylenedioxy group — which in other cathinones (methylone, ethylone, butylone) is associated with SERT activity — MDPV has negligible serotonergic activity. The pyrrolidine ring modification combined with the specific structural geometry appears to abolish SERT binding affinity. This is pharmacologically significant: there is no serotonergic "ceiling" moderating the dopaminergic stimulation, no entactogenic emotional component, and no MAOI-serotonin syndrome risk (though MAOI combination remains contraindicated due to noradrenergic activity).
Short Duration and Compulsive Pharmacokinetics
MDPV's peak effects last only 15–30 minutes when vaporized or insufflated, followed by an abrupt descent — the "fiend" effect documented in community accounts — that produces an intense desire to redose. This pharmacokinetic profile, combined with the exceptional DAT potency, creates a pharmacological machine for compulsive binge use. Animal self-administration studies show MDPV administration rates rivaling or exceeding cocaine.
Pharmacokinetics
MDPV is active at doses of 5–20 mg. Onset via insufflation or vaporization is rapid (2–5 minutes); oral onset is slower (15–30 minutes) with a longer, flatter curve. The brief peak duration is a primary driver of the compulsive use pattern.
Detection Methods
Standard Drug Panel Inclusion
MDPV (Methylenedioxypyrovalerone) is a substituted cathinone (synthetic cathinone) that is not included on standard 5-panel or 10-panel immunoassay drug screens. Some extended panels (particularly those marketed for "bath salts" detection) may include cross-reactive antibodies for the cathinone class, but coverage is inconsistent. The structural relationship to amphetamine means some cathinones trigger the amphetamine channel on immunoassays, but this is compound-specific and unreliable for MDPV (Methylenedioxypyrovalerone).
Urine Detection
MDPV (Methylenedioxypyrovalerone) and its metabolites can typically be detected in urine for 2 to 4 days following a single dose. Repeated or binge-pattern use may extend this window to 5 or more days. Primary metabolic pathways involve reduction of the beta-keto group, N-dealkylation, and hydroxylation. The resulting metabolites are excreted renally, often as glucuronide or sulfate conjugates.
Blood and Saliva Detection
Blood detection windows for MDPV (Methylenedioxypyrovalerone) range from 12 to 48 hours depending on dose and individual metabolism. Plasma concentrations decline rapidly due to extensive distribution into tissues. Oral fluid testing can detect MDPV (Methylenedioxypyrovalerone) for approximately 24 to 48 hours but is not commonly deployed for synthetic cathinones outside of specialized forensic settings.
Hair Follicle Detection
Hair analysis can detect synthetic cathinones including MDPV (Methylenedioxypyrovalerone) for up to 90 days. Incorporation into the hair shaft follows standard pharmacokinetic principles for basic amines. However, most commercial hair testing panels do not specifically target MDPV (Methylenedioxypyrovalerone), requiring custom LC-MS/MS methods with appropriate reference standards.
Confirmatory Testing
Definitive identification of MDPV (Methylenedioxypyrovalerone) requires instrumental analysis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for synthetic cathinones due to their thermal lability, which can cause degradation during gas chromatography. GC-MS remains usable but may require derivatization for optimal sensitivity. Reference standards specific to MDPV (Methylenedioxypyrovalerone) are necessary for quantitative confirmation.
Reagent Testing
Marquis reagent typically produces no reaction or a faint yellow-orange color with MDPV (Methylenedioxypyrovalerone). Mecke reagent may show no significant color change. Mandelin reagent can produce a yellow to brown reaction. The lack of strong, characteristic color reactions with common reagents makes cathinone identification by reagent testing alone unreliable. A combination of Marquis, Mecke, Mandelin, and Simon's reagents can help rule out other substance classes but cannot positively confirm MDPV (Methylenedioxypyrovalerone).
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Development
MDPV was first synthesized in 1969 by scientists at Boehringer Ingelheim as part of a research program into pyrrolidine cathinone derivatives. It was investigated for potential use as an ADHD medication and appetite suppressant, but was not developed for clinical use due to its high abuse potential — the irony of which would become apparent four decades later.
Emergence in the Designer Drug Market (2004–2011)
MDPV began appearing in forensic drug databases and NPS early warning systems in Europe around 2004–2005, initially as a minor component of the designer stimulant market. It gained commercial prominence in the "bath salts" product category in the late 2000s, sold alongside mephedrone and methylone in products marketed as "bath salts," "plant food," or "research chemicals" in head shops and online.
By 2010–2011, MDPV had become commercially prominent in the United States. Its potency and compelling euphoric properties drove rapid market growth. The product was typically sold in small foil pouches marketed with names like "Cloud Nine," "Ivory Wave," and "Vanilla Sky."
The Bath Salts Panic (2011–2012)
The period 2011–2012 saw intense media coverage of "bath salts" incidents, centered substantially on MDPV. High-profile cases of violent and erratic behavior — some accurately attributable to MDPV and some not — generated significant public alarm. The Miami "face-eating" incident in 2012, initially widely attributed to MDPV in media reports, was subsequently found by the medical examiner to involve marijuana rather than bath salts — but the damage to public perception was done. The episode significantly accelerated legislative action against MDPV and the bath salts category.
Scheduling and Aftermath
MDPV was placed into Schedule I in the United States in 2012 via emergency scheduling, among the first specific designer cathinones to receive this designation. Similar rapid controls were implemented across the EU, UK, Australia, and most other developed countries. MDPV's scheduling was followed by the emergence of structural analogs (A-PVP, A-PHP, MDPHP) designed to evade regulatory controls while maintaining pharmacological activity, demonstrating the structural arms race dynamic that characterizes the designer drug market.
Scientific Legacy
MDPV generated a substantial body of pharmacological and clinical research that significantly advanced understanding of the pyrrolidine cathinone class, the relationship between DAT potency and addiction liability, and the mechanisms of stimulant-induced psychosis.
Harm Reduction
An Honest Risk Assessment First
MDPV is pharmacologically exceptional in its capacity to produce severe harm. Any harm reduction discussion must begin with an honest acknowledgment: the available evidence from clinical case series, pharmacological research, and community experience consistently identifies MDPV as one of the highest-risk cathinones available. Strategies that are adequate for other substances may be insufficient for MDPV.
Test Your Substance
Reagent testing for cathinone class identification:
- Mecke: blue-green to black
- Marquis: orange to brown
- Fentanyl test strips: essential given prevalence of contamination in research chemical supplies
- Note: reagent testing identifies compound class but cannot assess potency
Dose with Extreme Precision
MDPV is active at single-digit milligram doses. The margin between a modest dose and an overwhelming one is very narrow:
- Use a 0.001g precision scale
- Volumetric dosing in solution (dissolving a known mass in a known volume of liquid and consuming measured aliquots) is the safest approach for this class
- Treat all unknown batches as potentially more potent than expected
The Fiend Cycle — Primary Harm
The 15–30 minute peak duration followed by abrupt descent is the primary driver of MDPV harm. Harm reduction strategies:
- Hard dose and dose-count limits set before any use
- Use with a trusted companion who has authority to physically intervene
- Physical removal of remaining material once the planned dose is administered
- Timed lockbox storage of any supply intended for later use
Emergency Protocol for Psychosis
MDPV psychosis is a medical emergency:
- Remove the person from access to additional MDPV
- Move to a calm, quiet, safe environment
- Benzodiazepines reduce acute agitation safely
- Call emergency services for severe symptoms, hyperthermia (temperature > 39°C / 102°F), or self-harm risk
- Inform medical personnel of MDPV use for appropriate treatment
Toxicity & Safety
Extreme Addiction Liability
MDPV has among the highest documented addiction liability of any synthetic cathinone or novel psychoactive substance. Its exceptional DAT potency, brief duration of peak effects, and rapid tolerance development create a pharmacological environment almost uniquely suited to compulsive binge use. Users who have lost control over MDPV use consistently describe a pattern that begins with recreation and rapidly transitions to continuous administration over multiple days with little sleep, food, or ability to stop.
Stimulant Psychosis
MDPV-associated psychosis is one of the most clinically documented harms in the NPS literature. Clinical case series from multiple countries document MDPV-induced paranoid psychosis with features including:
- Extreme paranoid delusions with threat content
- Visual and tactile hallucinations ("coke bugs" — sensation of insects under the skin)
- Aggressive behavior and agitation
- Marked hyperthermia and diaphoresis
- Duration of days to weeks in severe cases, outlasting the drug's pharmacological action
The mechanism is believed to involve sustained dopaminergic hyperactivation combined with severe sleep deprivation and catecholamine depletion.
Cardiovascular Toxicity
MDPV produces potent sympathomimetic cardiovascular effects. Deaths from cardiovascular complications have been documented in MDPV users. Severe hypertension, tachycardia, and hyperthermia are direct physiological consequences.
Hyperthermia
Life-threatening hyperthermia is a documented risk. Body temperatures exceeding 40°C (104°F) require emergency intervention.
Death Risk
Deaths directly attributable to MDPV — both from cardiovascular causes and from psychosis-associated trauma and accidents — have been documented in medical and forensic literature.
Drug Interactions
- MAOIs: Contraindicated — risk of hypertensive crisis
- Other stimulants: Multiplicative cardiovascular and psychiatric risk
- Alcohol: Masks toxicity warning signs
Overdose Information
overdose.
It is strongly recommended that one use harm reduction practices when using this drug.
More so than other stimulants, the chronic use of MDPV can be considered highly addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. Addiction is a serious risk among users of MDPV as it easily causes compulsive redosing and causes highly unpleasant comedown symptoms.
User reports indicate that chronic abuse or single exposure overdose of MDPV can potentially lead to psychosis more readily than the vast majority of stimulants. Psychotic symptoms from MDPV can include hearing voices, visual hallucinations, urges to harm oneself, severe anxiety, mania, grandiosity, paranoid delusions, confusion, increased aggression, and irritability.
- Stimulants** - MDPV can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
- MDMA** - The neurotoxic effects of MDMA may be increased when combined with amphetamine and other stimulants.
- Cocaine** - This combination may increase strain on the heart.
In September 2014, the European Council decided that MDPV shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.
- Australia: In Western Australia, MDPV has been banned under the Poisons Act 1964, having been included in Appendix A Schedule 9 of the Poisons Act 1964 as of February 11, 2012. The Director of Public Prosecutions for Western Australia announced that anyone intending to sell or supply MDPV faces a maximum $100,000 fine or 25 years in jail. Users face a $2000 fine or two years' jail. Therefore, anyone caught with MDPV can be charged with possession, selling, supplying or intent to sell or suppl
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | Develops rapidly with prolonged use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
In September 2014, the European Council decided that MDPV shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.
Australia: In Western Australia, MDPV has been banned under the Poisons Act 1964, having been included in Appendix A Schedule 9 of the Poisons Act 1964 as of February 11, 2012. The Director of Public Prosecutions for Western Australia announced that anyone intending to sell or supply MDPV faces a maximum $100,000 fine or 25 years in jail. Users face a $2000 fine or two years' jail. Therefore, anyone caught with MDPV can be charged with possession, selling, supplying or intent to sell or supply.
Austria: Since June 26, 2019, MDPV is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Belgium: MDPV is a controlled substance as of March 20, 2013.
Brazil: MDPV is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.
Bulgaria: MDPV is controlled under the Narcotic Substances Control Law as of February 2011.
Canada: On June 5, 2012 the Canadian Health Minister Leona Aglukkaq announced that MDPV would be listed on Schedule I of the Controlled Drugs and Substances Act, which was passed into law on September 26, 2012.
Croatia: MDPV is a controlled substance.
Cyprus: MDPV a Class B controlled substance, as it is covered by the cathinones catch-all clause.
Czech Republic: MDPV is a controlled substance.
Denmark: MDPV is a controlled substance.
Estonia : MDPV is a controlled substance as of November 29, 2010.
Finland: MDPV is specifically listed as a controlled substance in Finland (listed appendix IV substance as of June 28, 2010),
France: MDPV is a controlled substance as of August 2, 2012.
Germany: MDPV is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of July 26, 2012. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Hungary: MDPV a Schedule A controlled psychotropic substance.
Ireland: MDPV is covered by the Misuse of Drugs Acts since May 11, 2010.
Italy: MDPV is a controlled substance as of December 29, 2011.
Latvia: MDPV is a controlled substance.
Luxembourg: MDPV is a controlled substance as of July 30, 2012.
Norway: MDPV is a controlled substance as of Febuary 14, 2013.
Poland: MDPV is a controlled substance.
Slovakia: MDPV a Schedule I controlled psychotropic substance as of March 1, 2011.
Slovenia: MDPV is a controlled substance.
Sweden: MDPV is a controlled substance. In Sweden a 33-year-old man has been sentenced to six years in prison by an appellate court, Hovrätt, for possession of 250 grams of MDPV that had been acquired prior to criminalization.
Switzerland: MDPV is a controlled substance specifically named under Verzeichnis D.
Turkey: MDPV is a controlled substance.
United Kingdom: MDPV is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.
United States: On October 21, 2011, MDPV became a DEA federally scheduled drug. The DEA issued a temporary one-year ban on MDPV, classifying it as a schedule I substance. On December 8, 2011, under the Synthetic Drug Control Act, the US House of Representatives voted to ban MDPV and a variety of other synthetic drugs which had been sold legally in stores.
Responsible use
Research chemical
Stimulant
Substituted cathinone
Substituted pyrrolidine
Prolintane
MDPV (Wikipedia)
MDPV (Erowid Vault)
MDPV (Isomer Design)
MDPV (Drugs-Forum)
Discussion
MDPV Megathread (Bluelight)
Experience Reports (1)
Tips (5)
Do not combine MDPV with MAOIs or other serotonergic drugs. Many stimulants have serotonergic activity, and combinations can cause serotonin syndrome or hypertensive crisis, both medical emergencies.
Eat a substantial meal before taking MDPV. Stimulants suppress appetite heavily, and going many hours without food leads to worse crashes, irritability, and cognitive impairment. Set phone reminders to eat and drink.
Do not take MDPV in the afternoon or evening if you want to sleep that night. Most stimulants have long half-lives and even if you feel you can sleep, the quality will be significantly impaired.
Stay hydrated while using MDPV. Stimulants increase heart rate and body temperature while suppressing thirst signals. Sip water regularly, roughly 250-500ml per hour, more if dancing or in hot environments.
Weigh your dose of MDPV with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
See Also
References (5)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- PubChem: MDPV
PubChem compound page for MDPV (CID: 20111961)
pubchem - MDPV - TripSit Factsheet
TripSit factsheet for MDPV
tripsit - MDPV - Wikipedia
Wikipedia article on MDPV
wikipedia